Stock listing
Turquoise:PEGC Pharma Equity Group A/S Share Price
UK listing (Turquoise) of Pharma Equity Group A/S · home listing Copenhagen:PEG
Follow Pharma Equity Group A/S into a list and get an email when it puts out news.
Home listing price · OMXCOP:PEG
0.075 DKK +0.002 (+3.3%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, OMXCOP:PEG
- Day range
- 0.072 – 0.075 DKKNov 20, 2026
- Volume
- 107,662 sharesNov 20, 2026
- Market cap
- 91.82M DKKAt the close on Nov 20, 2026 · price × 1.23B shares outstanding
- 52-week range
- 0.060 – 0.120 DKKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 34,671 DKKMedian day 231,822 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Copenhagen:PEG · Home | 0.075 DKK | +0.002 (+3.3%) | 107,662 | 0.072 | 0.075 | 0.072 | 0.072 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXCOP:PEG · DKK, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 0.075 | +0.002 | +3.3% | 0.072 | 0.075 | 0.072 | 107,662 | |
| 0.072 | -0.003 | -4.0% | 0.073 | 0.078 | 0.072 | 159,004 | |
| 0.075 | -0.001 | -0.8% | 0.072 | 0.075 | 0.072 | 19,953 | |
| 0.076 | +0.003 | +4.7% | 0.072 | 0.079 | 0.072 | 238,820 | |
| 0.073 | 0.000 | 0.0% | 0.072 | 0.079 | 0.072 | 323,272 | |
| 0.073 | -0.007 | -9.0% | 0.080 | 0.080 | 0.072 | 570,809 | |
| 0.080 | +0.000 | +0.3% | 0.080 | 0.080 | 0.072 | 276,099 | |
| 0.080 | +0.010 | +13.7% | 0.085 | 0.085 | 0.079 | 642,693 | |
| 0.070 | -0.006 | -7.7% | 0.076 | 0.076 | 0.068 | 34,040 | |
| 0.076 | +0.006 | +8.3% | 0.076 | 0.076 | 0.070 | 240,141 | |
| 0.070 | -0.001 | -1.1% | 0.070 | 0.070 | 0.069 | 30,600 | |
| 0.071 | +0.003 | +3.8% | 0.068 | 0.071 | 0.068 | 482,860 | |
| 0.068 | -0.007 | -9.1% | 0.070 | 0.070 | 0.066 | 2,618,958 | |
| 0.075 | -0.003 | -3.8% | 0.078 | 0.083 | 0.075 | 595,286 | |
| 0.078 | -0.004 | -5.1% | 0.079 | 0.082 | 0.077 | 624,164 | |
| 0.082 | 0.000 | -0.2% | 0.085 | 0.085 | 0.079 | 1,459,463 | |
| 0.082 | +0.000 | +0.2% | 0.084 | 0.084 | 0.082 | 44,071 | |
| 0.082 | +0.004 | +5.1% | 0.081 | 0.083 | 0.080 | 1,739,859 | |
| 0.078 | -0.001 | -1.3% | 0.080 | 0.080 | 0.078 | 415,000 | |
| 0.079 | -0.001 | -1.0% | 0.080 | 0.080 | 0.079 | 10,374 | |
| 0.080 | +0.006 | +8.1% | 0.072 | 0.085 | 0.072 | 214,304 | |
| 0.074 | 0.000 | 0.0% | 0.076 | 0.076 | 0.074 | 761,092 | |
| 0.074 | -0.004 | -4.9% | 0.082 | 0.082 | 0.074 | 231,822 | |
| 0.078 | +0.007 | +10.5% | 0.085 | 0.085 | 0.075 | 303,792 | |
| 0.070 | -0.009 | -11.1% | 0.078 | 0.078 | 0.070 | 10,000 | |
| 0.079 | +0.002 | +2.3% | 0.080 | 0.080 | 0.064 | 947,090 | |
| 0.077 | +0.003 | +4.0% | 0.077 | 0.077 | 0.077 | 10,000 | |
| 0.074 | -0.002 | -2.4% | 0.073 | 0.074 | 0.073 | 141,736 | |
| 0.076 | -0.002 | -2.1% | 0.078 | 0.081 | 0.076 | 674,584 | |
| 0.078 | +0.000 | +0.3% | 0.078 | 0.079 | 0.078 | 1,643,801 | |
| 0.078 | +0.003 | +3.5% | 0.075 | 0.078 | 0.074 | 46,525 | |
| 0.075 | -0.005 | -6.3% | 0.075 | 0.078 | 0.075 | 1,302,081 | |
| 0.080 | +0.002 | +2.8% | 0.078 | 0.080 | 0.078 | 94,722 | |
| 0.078 | 0.000 | 0.0% | 0.078 | 0.078 | 0.078 | 295,000 | |
| 0.078 | +0.002 | +2.1% | 0.074 | 0.078 | 0.074 | 191,153 | |
| 0.076 | +0.001 | +1.6% | 0.077 | 0.077 | 0.071 | 55,563 | |
| 0.075 | -0.005 | -6.3% | 0.078 | 0.078 | 0.071 | 212,907 | |
| 0.080 | +0.002 | +3.1% | 0.089 | 0.089 | 0.080 | 279,071 | |
| 0.078 | -0.002 | -3.0% | 0.079 | 0.081 | 0.078 | 153,714 | |
| 0.080 | +0.007 | +9.6% | 0.080 | 0.080 | 0.080 | 46,450 | |
| 0.073 | -0.002 | -2.1% | 0.077 | 0.081 | 0.073 | 149,831 | |
| 0.075 | -0.004 | -4.6% | 0.080 | 0.082 | 0.075 | 819,929 | |
| 0.078 | -0.003 | -3.5% | 0.081 | 0.081 | 0.078 | 24,616 | |
| 0.081 | -0.001 | -1.5% | 0.078 | 0.082 | 0.078 | 114,851 | |
| 0.082 | +0.003 | +4.1% | 0.079 | 0.082 | 0.078 | 18,007 | |
| 0.079 | 0.000 | 0.0% | 0.080 | 0.085 | 0.079 | 435,737 | |
| 0.079 | -0.001 | -1.3% | 0.079 | 0.088 | 0.079 | 26,471 | |
| 0.080 | -0.001 | -1.2% | 0.080 | 0.080 | 0.079 | 312,685 | |
| 0.081 | 0.000 | 0.0% | 0.082 | 0.090 | 0.081 | 34,670 | |
| 0.081 | -0.001 | -1.5% | 0.081 | 0.081 | 0.081 | 67,270 | |
| 0.082 | +0.001 | +0.7% | 0.082 | 0.090 | 0.082 | 632,622 | |
| 0.082 | -0.003 | -4.0% | 0.084 | 0.084 | 0.080 | 81,798 | |
| 0.085 | +0.002 | +2.7% | 0.085 | 0.089 | 0.085 | 45,216 | |
| 0.083 | 0.000 | 0.0% | 0.084 | 0.086 | 0.083 | 159,045 | |
| 0.083 | +0.005 | +6.2% | 0.080 | 0.083 | 0.077 | 341,967 | |
| 0.078 | -0.006 | -7.6% | 0.080 | 0.082 | 0.077 | 1,338,226 | |
| 0.084 | -0.004 | -4.1% | 0.085 | 0.085 | 0.082 | 618,586 | |
| 0.088 | +0.003 | +3.3% | 0.085 | 0.088 | 0.084 | 283,684 | |
| 0.085 | -0.001 | -1.4% | 0.090 | 0.090 | 0.085 | 166,155 | |
| 0.086 | -0.002 | -1.8% | 0.088 | 0.090 | 0.085 | 1,782,094 | |
| 0.088 | +0.003 | +3.5% | 0.084 | 0.088 | 0.084 | 2,354,695 | |
| 0.085 | +0.001 | +1.0% | 0.084 | 0.085 | 0.084 | 31,022 | |
| 0.084 | +0.001 | +1.0% | 0.083 | 0.084 | 0.081 | 32,021 | |
| 0.083 | +0.001 | +1.7% | 0.085 | 0.085 | 0.081 | 365,973 | |
| 0.082 | -0.002 | -2.1% | 0.085 | 0.085 | 0.081 | 131,256 |
Splits
3 splits since 2016 · OMXCOP:PEG · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 2-for-1 | Split | |
| 1-for-10 | Consolidation | |
| 10-for-1 | Split |
- Ticker
- Turquoise:PEGC
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Turquoise
- Currency
- DKK
What changed lately
Latest news release · Sep 7, 2026
Pharma Equity Group A/S – Challenge to Arbitral Award
Latest news
Pharma Equity Group A/S – Challenge to Arbitral Award
Sep 7, 2026
Closed 0.082 (-4.0%) on Sep 8, 2026
Pharma Equity Group’s subsidiary Reponex takes key step forward in Inflammatory Bowel Disease with upcoming European patent grant
May 11, 2026
Closed 0.084 (+7.2%) on May 11, 2026
Proceedings of the Annual General Meeting of Pharma Equity Group A/S
Apr 17, 2026
Closed 0.086 (-2.5%) on Apr 20, 2026
Notice convening the annual general meeting in Pharma Equity Group A/S
Mar 25, 2026
Closed 0.082 (-4.9%) on Mar 26, 2026
Pharma Equity Group A/S - Annual Report 2025
Mar 25, 2026
Closed 0.086 (+0.9%) on Mar 25, 2026
Update of the Financial Calendar for 2026
Mar 18, 2026
Closed 0.09 (+6.1%) on Mar 18, 2026
Supplementary information (corrective information) to the annual report 2024 and the interim report for H1 2025
Feb 26, 2026
Closed 0.10 (-3.8%) on Feb 27, 2026
2026 Financial Calendar
Feb 3, 2026
Closed 0.107 (+5.4%) on Feb 3, 2026
Pharma Equity Group – Strategic update and adjustment of expectations
Dec 29, 2025
Closed 0.093 (-0.2%) on Dec 30, 2025
Pharma Equity Group executes on the Company's new strategy: Enters into Letter of Intent to acquire the MedTech company Otiom A/S
Dec 10, 2025
Closed 0.099 (-2.5%) on Dec 10, 2025
Pharma Equity Group A/S on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 13 in the last 12 months · 18 in all · newest Sep 7, 2026 · oldest 2025
- Decks
- 4 decks · latest Jun 1, 2023
Where Pharma Equity Group A/S is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Copenhagen:PEG · Home listing | Copenhagen | Denmark | DKK |
| Aquis:PEGC | Aquis | United Kingdom | DKK |
| Aquis:PEGC | Aquis | United Kingdom | DKK |
| LSE:0REU | LSE | United Kingdom | DKK |
| Turquoise:PEGC · This page | Turquoise | United Kingdom | DKK |
Valuation
Price/book 3.6× against a median of 0.9×: 6th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 102.5M DKK
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- 52.8×
- Price/book
- 3.6×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.4×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Pharma Equity Group A/S Class A · OMXCOP:PEG | US$13.47M | US$15.05M | n/a | n/a | 52.8× | 3.6× | n/a | 0.4× | n/a |
| TaiwanJ Pharmaceuticals Co., Ltd. · TPEX:6549 | US$13.68M | US$11.86M | n/a | n/a | n/a | 7.0× | n/a | 0.0× | n/a |
| Actuate Therapeutics, Inc. · NASDAQ:ACTU | US$13.60M | US$11.50M | n/a | n/a | n/a | n/a | n/a | n/a | 1.75 |
| BeyondSpring, Inc. · NASDAQ:BYSI | US$13.57M | US$12.99M | 0.3× | n/a | n/a | 0.9× | n/a | 0.0× | 1.31 |
| Acumen Pharmaceuticals, Inc. · NASDAQ:ABOS | US$13.49M | −US$38.84M | n/a | n/a | n/a | 0.4× | n/a | 0.8× | 1.45 |
| BioInvent International AB · OMXSTO:BINV | US$13.45M | −US$6.62M | n/a | −1.7× | n/a | 0.7× | n/a | 0.1× | n/a |
| Thalia Therapeutics PLC · LSE:THAT | US$13.36M | US$11.39M | n/a | 1,199× | n/a | 4.2× | n/a | 0.0× | n/a |
| Celyad Oncology SA · EURONEXT:CYAD | US$13.31M | US$13.21M | 14.6× | 573× | n/a | 9.7× | n/a | 0.0× | n/a |
| Defence Therapeutics Inc Class A · CSE:DTC | US$13.27M | US$13.16M | n/a | n/a | n/a | 5.4× | n/a | 0.5× | 0.74 |
| Tvardi Therapeutics, Inc. · NASDAQ:TVRD | US$13.22M | −US$9.05M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.89 |
| Diamyd Medical AB Class B · OMXSTO:DMYD_B | US$13.22M | −US$16.66M | n/a | −357× | n/a | 0.6× | n/a | 0.0× | n/a |
| Median of the others | US$13.40M | US$11.45M | 7.5× | 286× | 0.9× | 0.0× | 1.45 |
Team and board
Officers
| Officer | Role |
|---|---|
| Christian Tange | Chief Executive Officer |
| Lars Otto Uttenthal | Chief Medical Officer – Reponex Pharmaceuticals |
| Peter Ekman | Financial Manager |
Board
| Director | Role |
|---|---|
| Charlotte Pahl | Board Member |
| Christian Vinding | Board Director |
| Lars Gundorph | Board Member |
| Omar S. Qandeel | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2025 | Mar 20, 2025 · Before open | +1.1% |
| Q4 2024 | Nov 15, 2024 · Before open | −3.1% |
| Q3 2024 | Aug 16, 2024 · Before open | −3.0% |
| Q2 2024 | May 16, 2024 | +4.1% |
| Q1 2024 | Mar 29, 2024 | −7.2% |
| Q4 2023 | Nov 16, 2023 | +6.8% |
| Q3 2023 | Aug 16, 2023 | −7.7% |
| Q2 2023 | May 11, 2023 | 0.0% |
| Q1 2023 | Mar 31, 2023 | +5.8% |
| Q4 2022 | Nov 4, 2022 | +2.6% |
All 16 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2022 | Aug 22, 2022 | −2.7% |
| Quarter to Mar 31, 2022 | Apr 1, 2022 | −8.8% |
| Quarter to Sep 30, 2021 | Nov 5, 2021 | +18.4% |
| Q3 2021 | Aug 20, 2021 | −3.5% |
| Quarter to Mar 31, 2021 | May 13, 2021 | −4.4% |
| Q1 2021 | Mar 26, 2021 | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| H1 2023 Earnings Presentation | Earnings | 13 slides | Jun 1, 2023 |
| Investor Presentation (March 2023) | Investor deck | 16 slides | Mar 6, 2023 |
| Investor Presentation (March 2023) | Investor deck | 28 slides | Mar 1, 2023 |
| Reponex Pharmaceuticals — Merger or Acquisition (February 2023) | Merger or acquisition | 17 slides | Feb 10, 2023 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Convertible loans Announced: up to DKK 8.8M Use of proceeds: Repay existing convertible loans (DKK 600,000 and DKK 2,000,000 nominal) and a utilized credit facility of DKK 4,347,500 | Dec 1, 2025 | US$1.37M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in DKK
Income statement
| Line | FY2025 | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Cost of revenue | 0 | 311.0K | 0 | 235.0K | 0 | 480.0K | 0 | |||
| Gross profit | 0 | -311.0K | 0 | -235.0K | 0 | -480.0K | 0 | |||
| Research and development | 5.12M | 5.12M | 9.00M | 9.00M | 8.82M | 8.82M | 5.50K | |||
| Selling, general and administrative | 12.1M | 12.3M | 11.8K | 1.98M | 1.44M | 2.13M | 1.67M | |||
| Operating income | -17.2M | -25.3M | -21.3M | -21.3M | -20.6M | -25.3M | 3.03M | -1.44M | -17.6M | -1.67M |
| Depreciation and amortization | 311.0K | 311.0K | 235.0K | 235.0K | 218.0K | 480.0K | 539 | 236.6K | 206.3K | 171.9K |
| EBITDA | -16.9M | -25.0M | -21.1M | -21.1M | -20.4M | -24.8M | 3.03M | -1.21M | -17.4M | -1.50M |
| Interest expense | 2.65M | 2.65M | 4.96M | 4.96M | 1.56M | 1.56M | 996.0K | 665.0K | 272.0K | 30.0K |
| Income before tax | -26.4M | -26.4M | -42.4M | -26.2M | -26.6M | -26.8M | 3.48M | 5.39M | -32.9M | -14.4M |
| Income tax | -1.03M | -1.03M | -1.81M | -1.81M | -2.23M | -2.23M | -7.30M | -6.35M | 15.5M | 5.55M |
| Net income | -25.4M | -25.4M | -40.6M | -24.4M | -24.3M | -24.6M | 3.48M | 5.39M | -32.9M | -14.4M |
| Earnings per share, basic | -0.02 | -0.02 | -2.00 | -0.02 | -0.02 | -0.02 | 0.08 | 0.10 | -1.03 | -0.07 |
| Earnings per share, diluted | -0.02 | -2.00 | -0.02 |
Balance sheet
| Line | FY2025 | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 498.0K | 498.0K | 4.23M | 1.54M | 4.23M | 4.23M | 182.0K | 0 | 1.00K | |
| Receivables | 37.2M | 60.3M | 4.58M | 70.9M | 145.0K | 82.0K | 2.10M | |||
| Inventory | 1.00K | 1.59K | 71.3M | |||||||
| Current assets | 38.3M | 38.3M | 49.1M | 65.3M | 67.2M | 67.2M | 71.1M | 145.0K | 82.0K | 79.1M |
| Property, plant and equipment | 0 | 37.0K | 55.0K | |||||||
| Total assets | 38.9M | 38.9M | 49.4M | 65.6M | 67.7M | 67.7M | 71.1M | 63.6M | 57.6M | 80.8M |
| Accounts payable | 3.85M | 4.08M | 10.2M | 2.19M | 654.0K | 3.26M | 3.45M | |||
| Current liabilities | 8.83M | 8.83M | 8.63M | 8.63M | 34.3M | 34.3M | 25.0M | 14.5M | 23.3M | 5.24M |
| Long-term debt | 4.18M | 8.10M | 7.84M | 0 | 6.58M | |||||
| Total debt | 8.05M | 11.0M | 30.2M | 22.8M | 18.9M | 10.0M | 1.66M | |||
| Total liabilities | 13.4M | 13.4M | 16.7M | 16.7M | 42.4M | 42.4M | 25.0M | 21.1M | 23.3M | 13.7M |
| Shareholders' equity | 25.5M | 25.5M | 32.7M | 48.9M | 25.3M | 25.3M | 46.0M | 42.6M | 34.3M | 67.2M |
| Shares outstanding | 1.23B | 1.07B | 1.08B | 44.4M | 55.6M | 31.8M | 203.8M |
Cash flow
| Line | FY2025 | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -17.7M | -17.7M | -22.9M | -22.9M | -16.6M | -16.6M | -2.87M | -2.09M | -9.90M | -274.0K |
| Capital spending | -11.0K | -17.7M | 0 | 0 | -73.0K | -73.0K | 0 | 0 | 0 | -2.05M |
| Free cash flow | -17.7M | -17.7M | -22.9M | -22.9M | -16.7M | -16.7M | -2.87M | -2.09M | -9.90M | -2.32M |
| Cash from investing | -11.0K | 11.0K | 0 | -73.0K | -73.0K | 1.65M | ||||
| Cash from financing | 23.1M | 13.9M | 22.9M | 22.9M | 17.1M | 17.1M | 3.06M | 2.09M | 9.90M | -1.38M |
| Dividends paid | 0 | 0 | 0 | |||||||
| Change in cash | -3.73M | -3.74M | 3.00K | 3.00K | 363.0K | 1.40M | 182.0K | 0 |
Cap table
Built by 6ix from Pharma Equity Group A/S Class A’s releases · as of Dec 1, 2025
- Common shares
- 1,227,541,937
- Fully diluted
- 1,227,541,937
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,227,541,937 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,227,541,937 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Charlotte Pahl | Board Member · Since at least Apr 17, 2026 |
| Christian Tange | Chief Executive Officer · Since at least May 11, 2026 |
| Christian Vinding | Board Director · Since at least May 11, 2026 |
| Lars Gundorph | Board Member · Since at least Apr 17, 2026 |
| Lars Otto Uttenthal | Chief Medical Officer – Reponex Pharmaceuticals · Since at least Nov 5, 2026 |
| Omar S. Qandeel | Board Member · Since at least Apr 17, 2026 |
| Peter Ekman | Financial Manager · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Pharma Equity Group A/S.